Liquidia Corporation Intrinsic Stock Value – LIQUIDIA CORPORATION Reports 22.2% Year-Over-Year Increase in Q2 FY2023 Revenue of USD 4.8 Million
August 17, 2023
☀️Earnings Overview
On August 10 2023, LIQUIDIA CORPORATION ($NASDAQ:LQDA) reported its Q2 results for FY2023, showing total revenue of USD 4.8 million, a 22.2% increase from the same quarter last year. Net income for the quarter was USD -23.5 million, compared to -9.4 million from the prior year.
Analysis – Liquidia Corporation Intrinsic Stock Value
GoodWhale can provide deep insights into LIQUIDIA CORPORATION‘s fundamentals and help investors make informed decisions. According to GoodWhale’s proprietary Valuation Line, the fair value of LIQUIDIA CORPORATION share is around $6.4. However, currently the stock is trading at $7.9, which means it is overvalued by 22.5%. Investors should look into the company’s financials and other factors before deciding whether to buy or sell the stock. GoodWhale can help investors in this process by providing all the necessary information about the company. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Liquidia Corporation. More…
| Total Revenues | Net Income | Net Margin |
| 17.8 | -50.89 | -272.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Liquidia Corporation. More…
| Operations | Investing | Financing |
| -24.4 | -1.19 | 9.95 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Liquidia Corporation. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 121.6 | 60.94 | 0.94 |
Key Ratios Snapshot
Some of the financial key ratios for Liquidia Corporation are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 25.4% | – | -264.1% |
| FCF Margin | ROE | ROA |
| -143.7% | -41.3% | -24.2% |
Peers
The competition between Liquidia Corp and its competitors is fierce. Each company is vying for a share of the market, and each is eager to prove its superiority. Liquidia Corp is a leading player in the industry, and its competitors are well aware of this. They are all striving to beat Liquidia Corp at its own game, and they are all determined to win.
– Fusion Antibodies PLC ($LSE:FAB)
Fusion Antibodies PLC is a clinical-stage biopharmaceutical company focused on the development of novel antibody-based therapies for the treatment of cancer. The company’s lead product candidate is FT-7051, an antibody-drug conjugate (ADC) that is being evaluated in a phase 1/2 clinical trial in patients with advanced solid tumors. Fusion Antibodies PLC has a market cap of 10.02M as of 2022 and a Return on Equity of -20.87%.
– SinoMab BioScience Ltd ($SEHK:03681)
SinoMab BioScience Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibody therapeutics for the treatment of cancer and other unmet medical needs. The company’s lead product candidate is MMJ-001, a monoclonal antibody that targets the protein ROR1, which is overexpressed in various solid tumors and hematologic malignancies. SinoMab BioScience is headquartered in Beijing, China.
SinoMab BioScience Ltd has a market cap of 1.81B as of December 2020. The company’s ROE for the same period was -31.24%. The company’s lead product candidate is MMJ-001, a monoclonal antibody that targets the protein ROR1, which is overexpressed in various solid tumors and hematologic malignancies.
– TRACON Pharmaceuticals Inc ($NASDAQ:TCON)
TRACON Pharmaceuticals Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for cancer and other underserved medical needs. The Company’s product candidates include TRC105, TRC196 and TRC253. TRC105 is an endoglin antibody in Phase II clinical trials for the treatment of solid tumors. TRC196 is an antibody that inhibits angiopoietin-2 in Phase I/II clinical trials for the treatment of solid tumors. TRC253 is a small molecule kinase inhibitor in Phase I/II clinical trials for the treatment of solid tumors.
Summary
Investors are responding positively to LIQUIDIA CORPORATION‘s Q2 FY2023 earnings report. The company reported total revenue of USD 4.8 million, a 22.2% increase from the same period last year, and a net loss of USD -23.5 million, a decrease of -9.4 million year-over-year. Stock prices rose on the news, indicating investor confidence in the company’s performance and outlook. Overall, this report presents a positive outlook for the future of LIQUIDIA CORPORATION and may be an attractive opportunity for investors.
Related Posts
Recent Posts
